
中文名称:奈比洛尔
CAS号:118457-14-0
分子式: C22H25F2NO4 分子量: 405.43
产品形式: Free Base
研发状态: Recruiting
研发用途: Heart Failure
研究机构: Novartis Pharmaceuticals; Novartis
研发日期: April 4 2023
研发阶段: --
Nebivolol (Bystolic,R 065824) is a β1 receptor blocker with nitric oxide-potentiating vasodilatory effect used in treatment of hypertension and also for left ventricular failure.
中文名称: 他扎罗汀
CAS号:118292-40-3
分子式: C21H21NO2S 分子量: 351.46
产品形式: free base
研发状态: Completed
研发用途: Scalp Psoriasis
研究机构: Jinnah Postgraduate Medical Centre
研发日期: August 1 2022
研发阶段: Not Applicable
Tazarotene (AGN190168) is a retinoid prodrug of tazarotenic acid, which is a RAR agonist, used to treat psoriasis, acne, and sun damaged skin.
中文名称:拉呋替丁
CAS号:118288-08-7
分子式: C22H29N3O4S 分子量: 431.55
产品形式: free base
研发状态: Completed
研发用途: Gastric Ulcer
研究机构: Boryung Pharmaceutical Co. Ltd
研发日期: April 15 2016
研发阶段: Phase 1
Lafutidine (FRG-8813), a newly developed histamine H(2)-receptor antagonist, inhibits gastric acid secretion.
中文名称:唑来膦酸
CAS号:118072-93-8
分子式: C5H10N2O7P2 分子量: 272.09
产品形式: Free Base
研发状态: Not yet recruiting
研发用途: Copd; Empowerment; Empowerment Patient; Self Efficacy
研究机构: Zahide Aksoy; The Scientific and Technological Research Council of Turkey; Marmara University
研发日期: February 15 2024
研发阶段: Not Applicable
Zoledronic acid (ZA, Zoledronate, CGP-4244, GP42446A, ZOL 446, Zometa, Zomera, Aclasta, Reclast), a potent osteoclast inhibitor, induces apoptosis in osteoclasts by inhibiting enzymes of the mevalonate pathway and preventing the isoprenylation of small GTP-binding proteins such as Ras and Rho. Zoledronic acid (ZA) also induces autophagy.
中文名称:鸟苷
CAS号:118-00-3
分子式: C10H13N5O5 分子量: 283.24
产品形式: free base
研发状态: Recruiting
研发用途: Metabolic Syndrome; Coronary Microvascular Dysfunction
研究机构: Johns Hopkins University; Merck Sharp & Dohme LLC
研发日期: June 16 2023
研发阶段: Phase 2
Guanosine is a purine nucleoside comprising guanine attached to a ribose (ribofuranose) ring via a β-N9-glycosidic bond.
中文名称:雷贝拉唑
CAS号:117976-89-3
分子式: C18H21N3O3S 分子量: 359.44
产品形式: free base
研发状态: Active not recruiting
研发用途: Healthy Volunteers
研究机构: PMV Pharmaceuticals Inc
研发日期: September 19 2023
研发阶段: Phase 1
Rabeprazole(LY307640) is an oral inhibitor of proton pump and blocks the production of acid by the stomach.
即日起可免费注册成为会员, 建立企业产品库, 免费上传产品目录, 企业介绍等. 让你的产品直接呈现给客户.
试运营阶段,所有广告业务5折优惠
